Summary of Arrowhead Pharmaceuticals, Inc. R&D Webinar on Obesity/Metabolic Company Overview - **Company**: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - **Focus**: RNAi therapeutics platform with a pipeline of 14 clinical-stage assets across various therapeutic areas, including obesity and metabolic diseases [7][8] Key Themes and Insights Industry Context - **Obesity as a Disease**: The understanding of obesity is evolving; it is now recognized as a complex disease rather than merely a result of overeating [11][12][23] - **Need for Diverse Treatments**: There is a call for a variety of treatment options, including nutritional, pharmacological, and surgical therapies, to effectively address obesity [12][23] Scientific Insights - **Obesity Mechanisms**: New insights suggest that obesity may not just be a single disease but rather multiple subtypes, each requiring tailored treatments [14][15] - **Pharmacotherapy Advances**: Recent pharmacotherapies have shown promise, but there remains a significant portion of patients who do not respond effectively to current treatments [13][18][19] Pipeline Developments - **ARO-INHBE Program**: A new clinical program targeting the INHBE gene, which is linked to energy homeostasis and fat storage. Preclinical studies show that silencing this gene can lead to reduced body weight gain and improved metabolic profiles [24][28][30] - **ARO-ALK7 Program**: Another program targeting the ALK7 receptor, which is involved in lipid metabolism. Preclinical data indicate that silencing ALK7 can also reduce body weight gain without affecting lean muscle mass [42][46][48] TRiM Platform - **Adipose Tissue Targeting**: Arrowhead's TRiM platform aims to deliver RNA therapies directly to adipose tissue, which is crucial for metabolic disease treatment. The platform has shown effective gene silencing in adipocytes [35][36][39] - **Efficacy and Safety**: The TRiM platform demonstrated significant knockdown of target proteins in both mouse and non-human primate models, with a favorable safety profile [41][40] Clinical Trial Plans - **Phase 1/2a Studies**: Plans for clinical trials of ARO-INHBE and ARO-ALK7 in healthy volunteers with obesity, focusing on gene target knockdown and metabolic outcomes [55][56] - **Combination Studies**: Both programs will explore the effects of combining their therapies with existing treatments like tirzepatide to enhance efficacy [57] Market Considerations - **Long-term Health Outcomes**: The focus is shifting from weight loss as a primary goal to improving long-term health outcomes, which is increasingly recognized by payers and the healthcare system [60][61] - **Genetic and Biological Support**: The underlying genetics and biology of the INHBE and ALK7 pathways support their exploration as therapeutic targets for obesity [62] Conclusion - Arrowhead Pharmaceuticals is positioned to leverage its innovative RNAi platform and emerging understanding of obesity to develop novel therapies that address the multifaceted nature of the disease, with a strong emphasis on improving patient outcomes and maintaining lean mass during treatment [59][62]

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - Senior Vice President and Head of Global Cardiometabolic Franchise Ken Myszkowski - CFO James Hamilton - Chief Discovery and Translational Medicine Patrick O'Brien - COO and General Counsel Conference Call Participants Maury Raycroft - Jefferies Ellie Merle - UBS Luca ...

EXHIBIT 99.1 PRESS RELEASE August 8, 2024 Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results – Conference Call and Webcast Today, August 8, 2024 at 4:30 p.m. ET PASADENA, Calif., August 8, 2024 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead had a very productive quarter with several high- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ ARROWHEAD PHAR ...

If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 return is approximately 10%. At that rate the law of 72 states that an investor can expect their capital to double roughly every 7 years. Thus, those seeking 100% returns by 2025 will have to take some risks. There is effectively zero chance that an average strategy will double an investor’s returns within that time frame. That doe ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital Edward Tenthoff - Piper Sandler Maury Raycroft - Jefferies Brendan Smith - TD Cowen William Pickering - Bernstein Patrick Trucchio - H.C. Wainwright & Company O ...

EXHIBIT 99.1 PRESS RELEASE May 9, 2024 Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results – Conference Call and Webcast Today, May 9, 2024 at 4:30 p.m. ET PASADENA, Calif., May 9, 2024 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: " ...

Financial Performance - The company reported a net loss of $125.3 million for the three months ended March 31, 2024, compared to a net income of $48.7 million for the same period in 2023, marking a significant decline [88]. - Total revenue for the three months ended March 31, 2024, decreased by $146.3 million or 100.0% from the same period in 2023, primarily due to decreased revenue recognition from license and collaboration agreements [93]. - The company recorded a net loss per share – diluted of $1.02 for the three months ended March 31, 2024, compared to net income per share – diluted of $0.45 for the same period in 2023 [92]. Cash and Assets - The company had $127.7 million in cash, cash equivalents, and restricted cash as of March 31, 2024, an increase from $110.9 million as of September 30, 2023 [89]. - The company had total assets of $955.2 million as of March 31, 2024, compared to $765.6 million as of September 30, 2023 [89]. - Cash, cash equivalents, and restricted cash at the end of the period totaled $127.7 million as of March 31, 2024, compared to $135.0 million at the end of March 31, 2023 [108]. - The net increase in cash, cash equivalents, and restricted cash for the six months ended March 31, 2024, was $16.7 million, down from $27.2 million in the prior year [108]. Research and Development - Research and development expenses increased as the company's pipeline of candidates expanded and progressed through clinical trial phases [88]. - Total research and development expense was $101.1 million for the three months ended March 31, 2024, up from $74.9 million for the same period in 2023, representing a 35% increase [102]. - Candidate costs increased by $7.3 million, or 28%, for the three months ended March 31, 2024, and $10.3 million, or 15%, for the six months ended March 31, 2024 compared to the same period of 2023 [98]. - R&D discovery costs rose by $7.4 million, or 42%, for the three months ended March 31, 2024, and $23.9 million, or 79%, for the six months ended March 31, 2024 compared to the same period of 2023 [99]. - The company continues to develop other clinical candidates for future trials, with candidate costs expected to increase as development progresses [88]. - The company initiated a Phase 1/2a clinical trial of ARO-DM1 for type 1 myotonic dystrophy and filed for clearance to initiate a Phase 1/2a trial of ARO-CFB for complement-mediated renal disease [88]. Expenses - General and administrative expenses totaled $25.1 million for the three months ended March 31, 2024, an increase of $1.8 million, or 8%, compared to $23.2 million for the same period in 2023 [101]. - Salaries increased by $8.5 million, or 52%, for the three months ended March 31, 2024, and $16.4 million, or 53%, for the six months ended March 31, 2024 compared to the same period in 2023 [99]. - Facilities-related expenses increased by $2.5 million, or 72%, for the three months ended March 31, 2024, compared to the same period of 2023 [99]. - Depreciation and amortization expense increased by $1.8 million, or 81%, for the three months ended March 31, 2024, compared to the same period of 2023 [99]. - Other expense increased by $0.3 million and $2.8 million for the three and six months ended March 31, 2024, respectively, compared to the same periods of 2023 [105]. Cash Flow - Cash flow used in operating activities for the six months ended March 31, 2024, was $210.2 million, compared to $107.2 million for the same period in 2023, reflecting increased ongoing expenses related to research and development and administrative costs [108]. - Cash used in investing activities amounted to $204.1 million for the six months ended March 31, 2024, primarily due to capital expenditures of $102.7 million and investment purchases of $310.0 million, offset by proceeds from sales and maturities of investments of $208.6 million [108]. - Cash provided by financing activities was $431.0 million for the six months ended March 31, 2024, mainly from the issuance of common stock and stock option exercises, compared to $251.1 million in the same period in 2023 [108]. Other Information - The company completed enrollment in Amgen's Phase 3 OCEAN trial of olpasiran, triggering a $50.0 million milestone payment, which was received in Q3 of fiscal 2024 [88]. - There has been no material change in the Company's contractual obligations from the previous reporting period [109]. - The Company's exposure to market risk has not materially changed from the previous reporting period [110].

While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn’t received the same fervor. That could soon change.With the usual suspects in the digital innovation arena soaring to new heights, the law of large numbers will eventually kick in. For investors to get the same rewards they’ve been used to will likely require ...

After closing out 2023 with a 15.1% gain, the Russell 2000 looks even better this year in the new year. In fact, since Jan. 2, the index is up about 4% year to date, and could push even higher, taking some of the most undervalued Russell 2000 stocks along for the ride.According to Goldman Sachs, the Russell 2000 Index could return about 9% in the first six months of the year, and about 15% in the next 12 months. All thanks to low valuations, and an improving economic outlook. As noted by Investing.com, “The ...